Many TNBC (triple negative breast cancer) patients poorly respond to chemotherapy and radiotherapy due to EGFR (epidermal growth factor receptor) gene amplification and TP53 mutations [60, 61]. This evidence concerns the gene EGFR and triple-negative breast carcinoma.